425 with 319 randomized 278 evaluated: 138 IDS versus 140 no IDS
86 randomized with 7 37 IDS42 no IDS
FIGO stage
II-IV
IIB-IV
II-IV
Trial characteristics
RD > 1 cm after primary surgery and responding/stable after 3 cycles of Cisplatin/pacitaxelStage IV only pleural effusion
RD > 1 cm & maximum primary debulking not attempted in all cases with high proportion of RD >5 cm Randomization after 3 cycles of CP
Primary surgery and RD > 2 cm 1–4 CP Or 3 PAB followed by escalating CP
PFS for IDS versus No IDS
12.5 versus 12.7
18 versus 13
OS for IDS versus No IDS
36.2 versus 35.7
26 versus 20
15 versus 12 months
CP: cisplatin/cyclophosphamide; overall survival in months; PAB: cyclophosphamide/doxorubicine/bleomycin; PSF: progression free survival in months; RD: residual disease. was non suboptimum. begins at the start of the trial.